Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab dose-regimen study in fistulizing Crohn's disease
2015-000852-12Phase 4Terminated
- Sponsor
- Takeda
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vedolizumab in Crohn's disease (2 arms), sponsored by Takeda. Primary endpoint: At least 50% reduction in number of draining fistulae at Week 30. Started Mar 2016; status: terminated.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2015-000852-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000852-12.